Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 7,860,000 shares, an increase of 9.6% from the August 15th total of 7,170,000 shares. Based on an average daily trading volume, of 934,200 shares, the short-interest ratio is presently 8.4 days. Approximately 16.8% of the shares of the company are short sold.
Wall Street Analysts Forecast Growth
A number of brokerages recently weighed in on DCPH. SVB Leerink lifted their price objective on shares of Deciphera Pharmaceuticals from $21.00 to $25.00 and gave the company an "outperform" rating in a research note on Monday, September 12th. Cowen initiated coverage on Deciphera Pharmaceuticals in a research report on Monday, August 29th. They set an "outperform" rating and a $25.00 price objective for the company. Piper Sandler lifted their target price on shares of Deciphera Pharmaceuticals from $13.00 to $18.00 in a research report on Sunday, September 11th. JMP Securities raised Deciphera Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $23.00 price target on the stock in a research report on Friday, August 5th. Finally, HC Wainwright lifted their target price on shares of Deciphera Pharmaceuticals from $20.00 to $25.00 and gave the company a "buy" rating in a research note on Monday, September 12th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, Deciphera Pharmaceuticals currently has a consensus rating of "Hold" and a consensus target price of $17.90.
Get Deciphera Pharmaceuticals alerts:Institutional Investors Weigh In On Deciphera Pharmaceuticals
A number of institutional investors and hedge funds have recently made changes to their positions in DCPH. FMR LLC grew its position in shares of Deciphera Pharmaceuticals by 1.3% during the 2nd quarter. FMR LLC now owns 87,638 shares of the company's stock worth $1,152,000 after buying an additional 1,102 shares during the period. American International Group Inc. lifted its position in shares of Deciphera Pharmaceuticals by 6.8% in the second quarter. American International Group Inc. now owns 21,086 shares of the company's stock worth $277,000 after purchasing an additional 1,348 shares in the last quarter. Mariner LLC lifted its position in Deciphera Pharmaceuticals by 6.6% during the 1st quarter. Mariner LLC now owns 22,472 shares of the company's stock worth $208,000 after buying an additional 1,401 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in Deciphera Pharmaceuticals by 1.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 103,235 shares of the company's stock valued at $1,358,000 after purchasing an additional 1,592 shares during the last quarter. Finally, Ensign Peak Advisors Inc raised its stake in shares of Deciphera Pharmaceuticals by 4.4% during the 1st quarter. Ensign Peak Advisors Inc now owns 39,850 shares of the company's stock worth $369,000 after purchasing an additional 1,670 shares in the last quarter. Institutional investors own 72.29% of the company's stock.
Deciphera Pharmaceuticals Trading Up 0.9 %
Shares of DCPH stock traded up $0.16 during trading hours on Tuesday, hitting $18.77. The company had a trading volume of 15,786 shares, compared to its average volume of 992,926. Deciphera Pharmaceuticals has a 12 month low of $6.51 and a 12 month high of $20.88. The firm's fifty day moving average is $15.54 and its 200 day moving average is $12.39.Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.05. Deciphera Pharmaceuticals had a negative net margin of 231.99% and a negative return on equity of 74.37%. The firm had revenue of $32.49 million during the quarter, compared to analysts' expectations of $30.11 million. During the same quarter last year, the company posted ($1.21) EPS. The company's quarterly revenue was up 37.8% compared to the same quarter last year. Equities analysts anticipate that Deciphera Pharmaceuticals will post -2.5 earnings per share for the current fiscal year.
Deciphera Pharmaceuticals Company Profile
(Get Rating)
Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.
Featured Articles
- Get a free copy of the StockNews.com research report on Deciphera Pharmaceuticals (DCPH)
- Has AMD stock stock fallen too far?
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.